Table I.
Percentage of tumors with gene alterations in spontaneous human lung, oral, esophageal, stomach and colorectal cancers
| Lung
|
Oral
|
Esophagus
|
Stomach
|
Colon/rectum
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| % tumors with mutationsa | % tumors with LOH | % tumors with mutations | % tumors with LOH | % tumors with mutations | % tumors with LOH | % tumors with mutations | % tumors with LOH | % tumors with mutations | % tumors with LOH | |
| Cell cycle | ||||||||||
| BRCA1 | NA | NA | NA | NA | NA | 44 (42/96) | NA | 17 (11/64) | NA | 41 (201/494) |
| CDKN2A | 9 (45/494)b | NA | 7 (24/339)c | 60 (3/5) | 10 (69/700) | 59 (76/128) | 3 (9/354) | NA | 0 (0/77) | 19 (11/57) |
| CDKN2B | 0 (0/146) | 25 (2/8) | 0 (0/32) | NA | 2 (3/137) | NA | 0 (0/91) | NA | NA | NA |
| RB1 | 0 (0/21) | 47 (73/155) | NA | 12 (3/26) | 0 (0/49) | 40 (106/263) | NA | 31 (4/13) | 0 (0/33) | 14 (34/238) |
| TP53 | 42 (608/1457) | 49 (102/208) | 39 (261/661) | 48 (108/224) | 44 (1295/2928) | 57 (216/379) | 26 (749/2853) | 39 (148/375) | 40 (1368/3402) | 51 (606/1177) |
| Cell signaling: Wnt | ||||||||||
| APC | 1 (3/288) | 28 (20/72) | 4 (3/68) | 48 (11/23) | 2 (4/171) | 48 (99/207) | 18 (78/445) | 21 (81/383) | 36 (923/2563) | 33 (327/1004) |
| CTNNB1 | 0.8 (2/251) | NA | 0 (0/33) | NA | 0 (0/134) | NA | 4 (31/721) | NA | 6 (69/1199) | NA |
| Cell signaling: MAPK/ERK | ||||||||||
| BRAF | 2 (7/411) | NA | 0 (0/13) | NA | 11 (2/19) | NA | 1 (9/702) | NA | 14 (215/1559) | NA |
| HRAS | 1 (4/454) | 24 (21/89) | 11 (19/170) | 29 (7/24) | 0 (0/176) | 35 (6/17) | 2 (6/381) | 37 (7/19) | 1 (2/159) | 3 (1/35) |
| KRAS | 19 (506/2714) | NA | 4 (5/122) | NA | 2 (5/216) | NA | 6 (121/1949) | NA | 31 (2909/9504) | 0 (0/33) |
| NRAS | 1 (7/505) | NA | 0 (0/112) | NA | 0 (0/122) | NA | 2 (4/235) | NA | 6 (11/194) | NA |
| Cell signaling: apoptosis | ||||||||||
| DCC | NA | 41 (7/17) | NA | NA | NA | 26 (37/143) | NA | 33 (116/348) | NA | 48 (300/629) |
| FHIT | 2 (1/41) | 56 (199/353) | 0 (0/3) | NA | 34 (30/89) | 40 (61/153) | 5 (6/121) | 32 (79/248) | NA | 40 (58/146) |
NA, not available; ERK, extracellular signal-regulated kinase.
a
Mutations were somatic missense, nonsense and silent point mutations, frameshift deletions and insertions, in-frame deletions and insertions.
b
Values in parentheses show number of tumors with mutation/total number of tumors studied.
c
Values in parentheses show number of tumors with LOH/total number of informative samples.